Exacerbation of ulcerative colitis after rituximab salvage therapy. - Wikidata - awgldk - TriplyDB

Exacerbation of ulcerative colitis after rituximab salvage therapy.

Exacerbation of ulcerative colitis after rituximab salvage therapy.

http://www.wikidata.org/entity/Q45226801

about

Current stage in inflammatory bowel disease: What is next?Genetically engineered mouse models for studying inflammatory bowel disease Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity Interleukin-10 mediated autoregulation of murine B-1 B-cells and its role in Borrelia hermsii infection.Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab Design of targeted B cell killing agents.Crohn disease: a current perspective on genetics, autophagy and immunity Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves' disease.IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.Management of arthropathy in inflammatory bowel diseases.Resident bacteria-stimulated IL-10-secreting B cells ameliorate T cell-mediated colitis by inducing Tr-1 cells that require IL-27-signaling Inflammatory bowel disease associated arthropathy B cells and autoimmunity.B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis A new paradigm for an old story: the role of regulatory B cells in cancer Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.Integration of B cells and CD8+ T in the protective regulation of systemic epithelial inflammation.Investigational new drugs in the treatment of inflammatory bowel disease: a review.Fulminant Colitis Following Rituximab Therapy.B Cell in Autoimmune Diseases.Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis Reprogramming of B cells into regulatory cells with engineered fusokines Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice Activated B cells in autoimmune diseases: the case for a regulatory role.Hyperactivated B cells in human inflammatory bowel disease.Activation of human B cells negatively regulates TGF-β1 production.Regulatory B Cells in Pregnancy: Lessons from Autoimmunity, Graft Tolerance, and Cancer.Regulatory B cells in autoimmune diseases.Animal models of IBD: linkage to human disease.A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection.Colitis associated with biological agents Drug-induced inflammatory bowel disease and IBD-like conditions.Antibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality.Autophagy and intestinal homeostasis.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.

P2860

Q26777429-B93854B2-9DF6-4170-BF7C-9C7C94D38563 Q26783085-A6B8368D-AFD1-45A9-A0B1-CE4987A827DC Q26800155-9F88C8AC-3029-42E7-BA65-1AE5E0310490 Q33631177-CD9E3286-CA69-4A31-AFBD-4B604037D3F6 Q33741009-0E01D81C-031E-4613-BCD8-B06ED23282AF Q33934041-AA347E26-6ADB-4F17-9477-11ADFEF24A7F Q34132601-33E74F0E-9C81-441B-9D52-16317B497336 Q34493895-DBC3380B-1E86-4176-8C16-CD372F415965 Q34658996-6B7AEA6D-8485-4E05-A951-37EEBF9621B5 Q34755738-5AB16B34-B4B4-4380-8B23-D887E69FD2D7 Q34831296-FBDA5FEF-862C-4F5A-AA2F-9639EEA0DB72 Q35091366-9A27E61C-9995-4910-A5B0-96B04D33C329 Q35664427-5717CF2D-0A98-4365-A7A8-FFB199AC7CAB Q35680638-F3FC8162-66DC-459C-9CB7-4DE512B23F1C Q35706966-B5462B14-5246-4C03-B4D2-F2B0196A05F7 Q36034499-2C5C4257-A02D-492E-92BE-C98888FE11EC Q36093770-FBABF648-1C30-4A60-B9BE-17DF114589EC Q36107944-718FD75C-669B-4C5B-B140-2F1A5CDB20FF Q36745357-731E88AB-7D25-4CC2-9B42-283B82DBAC04 Q36782506-EBD37EFF-6ACE-4C2C-A1DD-DD555E62557C Q36890446-6995A330-D275-467C-8CB9-A09A415E5675 Q36897788-92108F72-01D3-4224-A807-6AFD768EFD1B Q36954468-85F1CCB4-FDD3-4382-81C7-ECA94674A663 Q37031308-63B1FB1F-D838-4E65-8010-01FBF0A61C7D Q37066073-758E8BFB-0772-4F3E-A2CB-E55C9020F571 Q37163714-225D5659-D16D-42FD-A765-6EBFDA990D33 Q37335863-7AF489DA-5954-4732-95CD-468E1BCD3796 Q37486515-FAD1E3FE-59E9-408C-84D3-573BF0029259 Q37593519-5C6DCA64-63A9-4D6F-9FDC-CB1ADAD44E57 Q37647575-ACD8A3BE-36C4-4014-9601-201014F360CE Q37729359-5CDF56BA-59EA-49EE-ACEF-D8FBB5B9CE18 Q37791260-75D3B13B-FE22-484E-ADBF-9FB3FA890766 Q37818921-BF1E9876-48D2-4933-A697-EFDA11F9F1B3 Q37846865-198E6959-5360-4558-BF19-FEB1999CA8DB Q38007938-B08BB48C-879B-47DC-B42F-75AD2275C08B Q38008983-433746B5-8F87-45CA-AC7B-2DC07458A11C Q38030235-22F9B75A-3982-4527-9321-8638193B0A78 Q38065286-EEC035B7-3523-4BE5-BF26-1DE864856C23 Q38071110-DC2EBB3E-DBCB-47D9-A889-65263B1BC9FC Q38132555-B8627FD8-2A01-4A20-8141-CE1A72649B54

P2860

Exacerbation of ulcerative colitis after rituximab salvage therapy.

http://www.wikidata.org/entity/Q45226801

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@en

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@nl

type

label

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@en

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@nl

prefLabel

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@en

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@nl

P1433

Q45226801-A3EE9813-CD48-4EED-ACE0-1B1C460AB2C3

P1476

Q45226801-7584B7CE-1A2B-470C-802A-8AF71728B8E7

P2093

Q45226801-1A76F3BE-3D12-49E0-9ACF-311C15D1AB3C

Q45226801-2B476C11-E3C2-4265-932E-DF6F959151F1

Q45226801-6A4A844E-7C2F-4A74-8A4D-74AC15A3992A

Q45226801-6AC4C589-E48E-4660-8A73-7715C4DCD640

Q45226801-DBDC9231-04FA-4794-B8C5-C4705D05F496

P2860

Q45226801-27082A99-F332-4177-A2D5-202A04148EC1

Q45226801-37962AE9-C7C9-482E-996D-D18C015D83D6

Q45226801-78F62EC8-DA81-485F-9F2C-762ECE7279C7

Q45226801-89466003-FB4F-4B24-9027-8840A41110AD

Q45226801-A528FB83-1A98-42B0-AA41-8F99765AB6E0

Q45226801-AC11C5E1-6314-4033-B168-06DCF84AB548

Q45226801-BD321A6A-1108-4CD5-8C12-1C4F47A0F457

Q45226801-D2FF5AF4-13EF-4393-A6F9-BC8F87C225E5

Q45226801-E686967E-14AC-472C-BE6A-0BBBDA532DF3

Q45226801-F0BCD8EF-66D8-4C93-9244-471BD36B4675

P304

Q45226801-9D05D1D2-5FF0-4C7A-A871-A9C2EBCE4FDC

P31

Q45226801-5707D5F9-243A-4820-93F1-32AE932AECE2

P356

Q45226801-63CAAEC6-9679-4B84-B5C7-643F0E0716EC

P433

Q45226801-A5C8F1E1-D094-44EA-B761-C884B1F61FB9

P478

Q45226801-5C1E5F6C-0058-4A2B-9A62-9641F4AF68D1

P577

Q45226801-5C399AF3-F858-49AE-AB4E-6B2CEF75F1CF

P5875

Q45226801-7DF36BD5-E6CF-4295-B13F-8F58895BEE8E

P698

Q45226801-DAE43B55-46F0-4741-8E5F-20AD8BA5AC17

P356

P1433

Inflammatory Bowel Diseases

P1476

Exacerbation of ulcerative colitis after rituximab salvage therapy.

@en

P2093

Markus F Neurath

http://www.w3.org/2001/XMLSchema#string

Martin Goetz

http://www.w3.org/2001/XMLSchema#string

Maryam Ghalibafian

http://www.w3.org/2001/XMLSchema#string

Peter R Galle

http://www.w3.org/2001/XMLSchema#string

Raja Atreya

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab for induction and maintenance therapy for ulcerative colitis

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets.

Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice.

The role of Th1/Th2 polarization in mucosal immunity.

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties.

Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria

Regulatory role of mature B cells in a murine model of inflammatory bowel disease.

P304

1365-1368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20215

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6233992

http://www.w3.org/2001/XMLSchema#string

P698

17604367

http://www.w3.org/2001/XMLSchema#string